Replimune’s mission is to revolutionize cancer treatment with therapies designed to activate a powerful and durable full-body anti-tumor response, boldly transforming cancer care because patient’s lives depend on it. We imagine a world where cancer is a curable disease.
At Replimune, we live by our values:
United: We Collaborate for a Common Goal.
Audacious: We Are Bold and Innovative.
Dedicated: We Give Our Full Commitment.
Candid: We Are Honest With Each Other.
People are at the center of everything we do, and when it comes to our employees, we make it personal. With a deep sense of purpose, an innovative and collaborative culture, a competitive and forward-looking total rewards program, everyone at Replimune has a unique opportunity to contribute to the meaningful work we do which could impact the lives of patients, caregivers and themselves.
Join us, as we reshape the future.
This function will serve as a field based medical expert and will be responsible for building/strengthening collaborative relationships in support of Replimune clinical development initiatives. This will be fulfilled mainly through the development of excellent working relationships with key opinion leaders, clinical sites, and internal stakeholders. Additional responsibilities include collection and internal dissemination of competitive intelligence, supporting portfolio expansion, and driving key pre-launch, launch, and post-marketing initiatives.
Candidates must live in the Mid Atlantic geography to be considered for this role.
Territory includes: Delaware, Maryland , Virginia, Washington DC area, North Carolina, South Carolina, WV, Philadelphia, Charlotte
Educational requirements:
Candidates must live in the Mid Atlantic geography to be considered for this role.
Territory includes: Delaware, Maryland , Virginia, Washington DC area, North Carolina, South Carolina, WV, Philadelphia, Charlotte
About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of a novel portfolio of oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.
We are an Equal Opportunity Employer.
Software Powered by iCIMS
www.icims.com